Pfizer Financial Results Exceed Wall Street Estimates for Revenue

Pfizer Inc. reported fourth-quarter 2025 financial results on Tuesday that surpassed Wall Street’s expectations for both revenue and earnings, even as the company continues to navigate a sharp decline in its COVID-19 franchise.

The pharmaceutical giant posted revenue of $17.56 billion for the quarter, beating the $16.95 billion anticipated by analysts. Adjusted earnings per share reached 66 cents, ahead of the 57 cents predicted. Despite these beats, the company recorded a GAAP net loss of $1.65 billion, a downturn from the $410 million profit reported in the same period last year, primarily due to restructuring charges and significant intangible asset impairment costs.

The decline in pandemic-era demand remains a headwind, with Comirnaty vaccine revenues falling 35% and the antiviral Paxlovid dropping 70%. However, Pfizer’s non-COVID portfolio showed resilience, growing 9% operationally in the fourth quarter. Key growth drivers included the RSV vaccine Abrysvo, which saw a 136% operational increase, and the Vyndaqel family of heart treatments.

Central to Pfizer’s future growth is its high-stakes entry into the weight-loss market. The company recently completed its $10 billion acquisition of Metsera and on Tuesday released positive Phase 2b data for an ultra-long-acting obesity injection. The study met its primary endpoint, showing significant weight loss that continued even as patients switched to once-monthly dosing.

Looking toward 2026, Pfizer reaffirmed its outlook of $59.5 billion to $62.5 billion in revenue. This guidance incorporates anticipated impacts from "price compression" linked to a landmark drug pricing deal with the Trump administration. Under this agreement, Pfizer will provide deeper discounts to Medicaid in exchange for a three-year exemption from tariffs.

As the company works to cut $7.7 billion in costs by 2027, leadership remains focused on its late-stage pipeline, planning to start approximately 20 key pivotal studies in 2026 to offset upcoming losses of exclusivity on older blockbuster drugs.k rather than a threat to the company’s long-term cash flow from its GLP-1 portfolio.

---

🔖 Sources

Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance

Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook

Pfizer Sales Fall on Continued Lower Covid-19 Drug Demand

---

Keywords: Pfizer Financial Results

Pfizer Financial Results

---